Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland. Show more

9, RUE DE BITBOURG, LUXEMBOURG, LUXEMBOURG, 1273, Luxembourg, 1273, USA

https://www.alvotech.com

DRUG MANUFACTURERS - SPECIALTY & GENERIC

HEALTHCARE

Start AI Chat

Market Cap

1.859B

52 Wk Range

$2.94 - $9.25

Previous Close

$5.21

Open

$5.21

Volume

540,857

Day Range

$5.14 - $5.34

Enterprise Value

3.168B

Cash

142.8M

Avg Qtr Burn

-19.79M

Insider Ownership

59.68%

Institutional Own.

12.72%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Denosumab (AVT03) (RANKL Inhibitor) Details Osteoporosis And Bone Metastases	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Selarsdi/Ustekinumab (AVT04) (IL-12/23 Inhibitor) Details Autoimmune And Inflammatory Disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVT05 (Proposed Biosimilar to Simponi® & Simponi Aria® (golimumab)) Details Inflammatory disease	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mynzepli® (AVT06, a Proposed Biosimilar to Eylea®) (aflibercept) Details Eye disease	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Entyvio/Vedolizumab (AVT16) (Integrin Antagonist) Details Ulcerative Colitis And Crohn's Disease	BLA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Omalizumab (AVT23) (IgE Antibody) Details Allergic Asthma And Urticaria	BLA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Entyvio/Vedolizumab (AVT80) (Integrin Antagonist) Details Ulcerative Colitis And Crohn's Disease	BLA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVT29 (VEGF Inhibitor) Details Eye Disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.